$GSK News

GSK Announces Cabenuva Demonstrates Superiority To Daily Oral Therapy In Adolescents Living With HIV, As Viiv Healthcare Highlights New Long-Acting Injectable Data At AIDS 2026

GSK plc (GSK) Q2 2026 Earnings Call Transcript

GSK Races To Protect Profits Before Its HIV Blockbuster Faces Generic Rivals

GSK: Healthy Results, But Limited Stock Upside (Rating Downgrade)

GSK plc 2026 Q2 - Results - Earnings Call Presentation

GSK FY2031 Revenue expected to be more than $53.204B vs $45.690B Est

GSK Affirms FY2026 Adj EPS Guidance of $4.90-$5.00 vs $4.79 Est; Affirms FY2026 Sales Guidance of $44.754B vs $45.690B Est

GSK Q2 Adj. EPS $1.35 Beats $1.27 Estimate, Sales $11.280B Beat $10.790B Estimate

GSK Licensor Hansoh Pharma Announces Results From Second Phase III Trial For Ris-Rez In China; Study Met Its Primary Endpoint Of Progression-Free Survival In Relapsed Osteosarcoma

FDA Greenlights GSK’s First Lung Cancer Drug Ahead of Schedule

GSK Wins FDA Approval For Jideytro To Treat Previously Treated ROS1-Positive Non-Small Cell Lung Cancer

GSK shares are trading lower after the company announced that it will cease further development of Camlipixant as a chronic cough treatment due to its failure to meet statistical significance in two clinical trials.

Disappointing Data Prompts GSK to Drop Cough Drug Development

GSK Plans To Stop Further Development Of Camlipixant In Refractory Chronic Cough As Camlipixant 25mg Twice Daily Failed To Meet Statistical Significance In CALM-1, CALM-2 Clinical Trials

GSK's Jemperli May Help Some Rectal Cancer Patients Avoid Surgery

GSK's Licensing Partner Hansoh Pharmaceutical Announces That Risvutatug Rezetecan Met The Primary Endpoint Of Overall Survival In The ARTEMIS-008 Phase 3 Clinical Trial For Patients With Small Cell Lung Cancer

GSK Terminates Collaboration, License Agreement With Alector, Effective Jan. 2, 2027; Alector Repays $10.429M

GSK's Exdensur Receives Canada Approval To Treat Severe Asthma, Chronic Rhinosinusitis With Nasal Polyps

GSK's Momelotinib Receives Orphan Drug Designation From FDA And European Medicines Agency For VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

GSK plc (GSK) M&A Call Transcript